Doxorubicin-Induced Cardiotoxicity: Molecular Mechanism and Protection by Conventional Drugs and Natural Products
International Journal of Clinical Oncology and Cancer Research
Volume 2, Issue 2, April 2017, Pages: 31-44
Received: Feb. 9, 2017; Accepted: Mar. 1, 2017; Published: Mar. 20, 2017
Views 1329      Downloads 129
Authors
Hayder M. Alkuraishy, Department of Clinical Pharmacology and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
Ali I. Al-Gareeb, Department of Clinical Pharmacology and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
Hany Akeel Al-hussaniy, Bsc Pharmacist, Ministry of Health, Baghdad, Iraq
Article Tools
Follow on us
Abstract
Doxorubicin is useful anticancer drug because it's used in treatment of acute leukemia, Hodgkin's and non-Hodgkin's lymphomas, and many other malignant neoplasm. The mechanism of doxorubicin induce cardiotoxicity is multifactorial includes free radical stress, mitochondrial dysfunction and calcium overload these are the main causes of doxorubicin-induced cardiotoxicity. Doxorubicin therapy augments oxidative stress and disturbs cytosolic calcium homeostasis, increases intracellular calcium levels from the sarcoplasmic reticulum through activation of the ryanodine receptor and by blighting calcium clearance systems in cardiomyocytes. In this condition the researchers trying to develop cardio-protective strategy to decrease this cardio-toxic effect without decreasing its anticancer effect. Now day's oncologists and pharmacologist work to find out how to decrease the cardiovascular risk and prevent doxorubicin adverse cardiovascular effect. Therefore, the aim of this study was to illustrate the molecular mechanism and possible amelioration of doxorubicin induced-cardiotoxicity via conventional drugs and natural products.
Keywords
Doxorubicin, Cardiotoxicity, Natural Products
To cite this article
Hayder M. Alkuraishy, Ali I. Al-Gareeb, Hany Akeel Al-hussaniy, Doxorubicin-Induced Cardiotoxicity: Molecular Mechanism and Protection by Conventional Drugs and Natural Products, International Journal of Clinical Oncology and Cancer Research. Vol. 2, No. 2, 2017, pp. 31-44. doi: 10.11648/j.ijcocr.20170202.12
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Adams, M. J. and Lipshultz, S. E., "Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: Implications for screening and prevention.." Pediatric blood & cancer, 2005: 600-606.
[2]
Ahmed, Ihab A., A. I. Al-Gareeb, and Khaleel. Khaled J. "Ameliorating the anticancer drug ”Adriamycin” acute Cardiotoxicity by Rosuvastatin and Telmisartan in rats." Iraqi Journal of Cancer and Medical Genetics, 2014: Volume 7 - Number 2 – 2014 p 146-152.
[3]
Akaberi, M, and M. and Mehri, S Iranshahi. "Molecular signaling pathways behind the biological effects of Salvia species diterpenes in neuropharmacology and cardiology." Phytotherapy Research, 2016: 30 (6), pp. 878-893.
[4]
Al Kuraishy, H. M. and Al Gareeb, A. I. "Central beneficial effects of trimetazidine on psychomotor performance in normal healthy volunteers." Advanced Biomedical Research, 2016.
[5]
Alkuraishy, H. M, A I Algareeb, A. K Albuhadilly, and B M ALmgoter. "Modulation Effects of piracetam and Ginkgo biloba on the cognitive and working memory functions: Psychometric study.." Current Psychopharmacology, 2014: 3 (2), pp. 87-92.
[6]
Alkuraishy, H. M, A. I Algareeb, and A. K. and ALmgoter, B. M Albuhadilly. "Potential additive effects of garcinia cambogia on atorvastatin treated hyperlipidemic patients: randomized crossover clinical study." Int J Adv Med, 2014: Nov; (3): 189-195.
[7]
Al-Kuraishy, H. M, A. I Al-Gareeb, M. S. and Alrifai, S. B Awad, and. "Assessment of serum prolactin levels in acute myocardial infarction: The role of pharmacotherapy." Indian journal of endocrinology and metabolism, 2016: 20 (1), p. 72.
[8]
Alkuraishy, H. M, and Algareeb, A. l. 2013. Basim S. N. Al-Mgote. " Dual effects of aspirin and Garcinia Cambogia on human blood viscosity." Zanco J. Med, 2013: Vol. 17, No. (3), pp 514–517.
[9]
Al-Kuraishy, H. M, and K. J. and Mohammed, M. A Khaleel. " Significant attenuation and amelioration effects of labetalol in doxorubicin induced cardiotoxicity: An animal model study." Journal-Cardiovascular Surgery, 2015.: 3 (2), pp. 25-29.
[10]
AlKuraishy, H. M. and Al-Gareeb, A. I. "Interleukin-17: a cardiac biomarker in estimation of cardioprotective effects of tacrolimus in doxorubicin-induced cardiotoxicity: animal model study." 2015.
[11]
AlKuraishy, H. M., and A. I Al-Gareeb. "Cardio-protective effects of cyclosporine in doxorubicin induced cardiotoxicity and assessment of Interleukin-17 as biomarker of cardiac injury: an animal model study." Adv. Biomed. Pharma., 2015: 2: 3. 138-145.
[12]
Al-Kuraishy, H. M., and A. I Al-Gareeb. "Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile." Journal of Basic and Clinical Pharmacy, 2017: 8 (1), p. 8.
[13]
Al-Kuraishy, H. M., and A. I Al-Gareeb. "Potential effects of pomegranate on lipid peroxidation and pro-inflammatory changes in daunorubicin-induced cardiotoxicity in rats." International Journal of Preventive Medicine, 2016: 7.
[14]
Alkuraishy, H. M., and A. I. Al-Gareeb. "Advances and Prospects of Nicardipine Effects in Attenuation of Hydroxy-Daunorubicin Induced Acute Cardiotoxicityin rats." Adv. Biomed. Pharma., 2015: 2: 6 (2015) 274-282.
[15]
AlKuraishy, H. M., and A. I. Al-Gareeb. "PRE-TREATMENT WITH LISINOPRIL AND/ OR LOVASTATIN LESSEN AND AMELIORATE CARDIOTOXICITY OF DOXORUBICIN IN RATS animal model study,." ejbps, Volume 2, Issue 4,, 2015: 833-847.
[16]
Alkuraishy, H. M., and A. I. and Al-windy, S. Al-Gareeb. "Alkuraishy, H. M., Al-Gareeb, A. I. and Al-windy, S., Cardio-protective effects of cyclosporine in doxorubicin induced cardiotoxicity and assessment of Interleukin-17 as biomarker of cardiac injury: an animal model study, Adv. Biomed. Pharma. 2: 3 (2015) 1." Adv. Biomed. Pharma., 2015: 138-145.
[17]
Alkuraishy, H. M., and S Alwindy. "Beneficial effects of silymarin on lipid profile in hyperlipidemic patients: placebo controlled clinical trail." 2012.
[18]
Al-kuraishy, Hayder M., and Ali I. Al-Gareeb. "Advances and Prospects of Nicardipine Effects in Attenuation of Hydroxy-Daunorubicin Induced Acute Cardiotoxicity in rats." Adv. Biomed. Pharma, 2015: 274-282.
[19]
Al-Kurashiy, H. M, I. N Abdalwahab, A. I. Algareeb, and S. B Alwindy. "Effects of Carvedilol on the Exercise Parameters.." Journal of Al-Nahrain University, 2011: Vol. 14 (4), December, pp. 121-125.
[20]
Allen, T. M. and Cullis, P. R. " Liposomal drug delivery systems: from concept to clinical applications." Advanced drug delivery reviews, 2013: 65 (1), pp. 36-48.
[21]
Al-Nimer, M. S, A. I. A. AL-Gareeb, and H. M Al-Kuraishy. " The Clot-lysis Effect of Selective α1-Adrenoceptor Antagonist in Vitro Model Associated with High Peroxynitrite Level." IRAQI POSTGRADUATE MEDICAL JOURNAL, 2011: 10 (2).
[22]
Alyane, M, G. and Lahouel, M Barratt, and. " Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells." Saudi Pharmaceutical Journal, 2016: 24 (2), pp. 165-175.
[23]
Attia, S. M., Ahmad, S. F., Ansaria, M. A., A. Nadeem, O. A. Al-Shabanah, and M. M. and Bakheet, S. A.,. Al-Harbi. " Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells." PloS one, 2016: 11 (9), p. e0163703.
[24]
Bachur, N. R, and S. L. and Gee, M. V Gordon. "A general mechanism for microsomal activation of quinone anticancer agents to free radicals." Cancer Research, 1978: 38 (6), pp. 1745-1750.
[25]
Baselga, J., L. Norton, H. Masui, A. Pandiella, K. Coplan, and W. H. and Mendelsohn, J. Miller. "Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies." Journal of the National Cancer Institut, 1993: 1327-1333.
[26]
Brunet, A, S. R. Datta, and M. E Greenberg. "Transcription-dependent and-independent control of neuronal survival by the PI3K–Akt signaling pathway.." Current opinion in neurobiology, 2001: 11 (3), pp. 297-305.
[27]
Büntzel, I, D. Fröhlich, and M Glatzel. "Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer." Annals of Oncology, 1998: 9 (5), pp. 505-509.
[28]
Cabanillas, F., M. A. Burgess, and G. P. and Freireich, E. J., Bodey. "Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type." The American journal of medicine, 1983: 382-388.
[29]
Callaghan, R., and F. and Bebawy, M. Luk. " Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?.." Drug Metabolism and Disposition, 2014: 623-631.
[30]
Carvalho, F. S., A. Burgeiro, R. Garcia, A. J. Moreno, R. A. Carvalho, and P. J. Oliveira. "Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy." Medicinal research reviews, 2014: 106-135.
[31]
Cersosimo, R. J. and Hong, W. K. "Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue." Journal of Clinical Oncology, 1986: 425-439.
[32]
Chen, J. J., P. T. Wu, H. R Middlekauff, and K. L., and Nguyen. "Aerobic Exercise in Anthracycline-Induced Cardiotoxicity: A Systematic Review of Current Evidence and Future Directions." American Journal of Physiology-Heart and Circulatory Physiology, 2016: ajpheart-00646.
[33]
Ciocca, D. R, S Oesterreich, G. C Chamness, and W. L. and Fuqua, S. A MCGuire. "Biological and clinical implications of heat shock protein 27000 (Hsp27): a review." Journal of the National Cancer Institute, 1993: 85 (19), pp. 1558-1570.
[34]
Ciocca, D. R., and S. K Calderwood. " Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications.." Cell stress & chaperones, 2005: 10 (2), pp. 86-103.
[35]
Dakic, A., DiVito, K., Fang, S., Suprynowicz, F., Gaur, A., Li, X., Palechor-Ceron, N., V. Simic, S. Choudhury, S. Yu, and C. M. Simbulan-Rosenthal. "ROCK inhibitor reduces Myc-induced apoptosis and mediates immortalization of human keratinocytes." Oncotarget, 2016: 66740-66753.
[36]
Dakic, A., et al. "ROCK inhibitor reduces Myc-induced apoptosis and mediates immortalization of human keratinocytes." Oncotarget, 2016: 7 (41), pp. 66740-66753.
[37]
Diamanti, J., et al. "Doxorubicin-induced oxidative stress in rats is efficiently counteracted by dietary anthocyanin differently enriched strawberry (Fragaria× ananassa Duch.)." Journal of agricultural and food chemistry, 2014: 3935-3943.
[38]
Heather Greenlee, Jacquelyn Shaw, Ying-Ka Ingar Lau, Ali Naini, PhD, Matthew Maurer. Effect of Coenzyme Q10 on Doxorubicin Cytotoxicity in Breast Cancer Cell Cultures. Integr Cancer Ther. 2012; 11 (3): 10.
[39]
Egan, P. C., M. E. Costanza, P. Dodion, and M. J. and Bachur, N. R., Egorin. " Doxorubicin and cisplatin excretion into human milk." Cancer treatment reports, 1985.: 1387-1389.
[40]
El-Sayed, E. S. M, and A. M. and Abdul-Hameed, M. S Mansour. "Thymol and carvacrol prevent doxorubicin-induced cardiotoxicity by abrogation of oxidative stress, inflammation, and apoptosis in rats." Journal of biochemical and molecular toxicology, 2016: 30 (1), pp. 37-44.
[41]
Ewer, M. S., and S. M Lippman. "Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity." Journal of Clinical Oncology, 2005: 23 (13), pp. 2900-2902.
[42]
Fimognari, C, M Lenzi, D Sciuscio, G. I. O. R. G. I. O. CANTELLI-FORTI, and P Hrelia. "Combination of Doxorubicin and Sulforaphane for Reversing Doxorubicin-Resistant Phenotype in Mouse Fibroblasts with p53Ser220 Mutation." Annals of the New York Academy of Sciences, 2007: 1095 (1), pp. 62-69.
[43]
Herman, E. H, et al. "Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin." Journal of Clinical Oncology, 1999: 17 (7), pp. 2237-2237.
[44]
Herman, E. H, et al. "Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity." Cancer research, 1998: 58 (2), pp. 195-197.
[45]
HOSSEINI, A. and MAHDIAN, D. "PROTECTIVE EFFECT OF LACTUCA SERRIOLA ON DOXORUBICIN-INDUCED TOXICITY IN H9C2 CELLS." Acta poloniae pharmaceutica, 2016: 73, p. 659.
[46]
Huang, Y. "2016. Clinical application and functional characterization of TOX in cutaneous T-cell lymphoma." University of British Columbia), 2016: Doctoral dissertation.
[47]
Inoue, H. and Tani, K.,. " Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments." Cell Death & Differentiation, 2014: 39-49.
[48]
Iqbal, M, K Dubey, T Anwer, and A. and Pillai, K. K Ashish. " Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats." Pharmacological Reports, 2008: 60 (3), p. 382.
[49]
J Kapadia, G, M A Azuine, G Subba Rao, T Arai, and A. and Tokuda, H Iida. "Cytotoxic effect of the red beetroot (Beta vulgaris L.) extract compared to doxorubicin (Adriamycin) in the human prostate (PC-3) and breast (MCF-7) cancer cell lines.". Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2011: 11 (3), pp. 280-284.
[50]
Jin, L., Hu, W. L., Jiang, C. C., Wang, J. X., Han, C. C., Chu, P., Zhang, L. J., Thorne, R. F., Wilmott, J., Scolyer, R. A. and Hersey, P., "MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma." Proceedings of the National Academy of Sciences, 2011: 15840-15845.
[51]
Jones, S. E., et al. "Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.." Journal of Clinical Oncology, 2006: 5381-5387.
[52]
Kaiserová, H, et al. " New iron chelators in anthracycline-induced cardiotoxicity." Cardiovascular toxicology, 2007: 7 (2), pp. 145-150.
[53]
Kalyanaraman, B. J. S. S. E. S., J. Joseph, S. Kalivendi, S. Wang, and E. and Kotamraju, S. Konorev. "Doxorubicin-induced apoptosis: implications in cardiotoxicity. In Oxygen/Nitrogen Radicals: Cell Injury and Disease." Springer US., 2002: 119-124.
[54]
Kehrer, J. P. "Kehrer, J. P; 1993. Free radicals as mediators of tissue injury and disease." Critical reviews in toxicology, 1993: 23 (1), pp. 21-48.
[55]
Kim, H. K, et al. "Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain." Pain, 2004: 111 (1), pp. 116-124.
[56]
Komaki, R, et al. "Effects of amifostine on acute toxicity from concurrent chemotherapy andradiotherapy for inoperable non–small-cell lung cancer: Report of a randomized comparative trial." International Journal of Radiation Oncology* Biology* Physics, 2004: 58 (5), pp. 1369-1377.
[57]
Li, Y., B. Xu, T, Bai, and W., 2015. Liu. "Co-delivery of doxorubicin and tumor-suppressing p53 gene using a POSS-based star-shaped polymer for cancer therapy. Biomaterials." Biomaterials, 2015: 12-23.
[58]
Liu, J. "Pharmacology of oleanolic acid and ursolic acid." Journal of ethnopharmacology, 1995: 49 (2), pp. 57-68.
[59]
Llesuy, S. F, J Milei, H Molina, and A. and Milei, S Boveris. "Comparison of lipid peroxidation and myocardial damage induced by adriamycin and 4'-epiadriamycin in mice.,." Tumori, 1985: 71 (3), pp. 241-249.
[60]
Loveless, H., E. Arena, and R. L. and Bachur, N. R. Felsted. "Comparative mammalian metabolism of adriamycin and daunorubicin." Cancer Research, 1978: 593-598.
[61]
Lushchak, V. I. " Free radicals, reactive oxygen species, oxidative stress and its classification." Chemico-Biological Interactions, 2014: 164-175.
[62]
Friedman R, Caflisch A. Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring. ChemMedChem. 2009; 4 (8): 1317-26
[63]
Mazevet, M, M Moulin, A Llach-Martinez, C Chargari, É Deutsch, and A. M. and Morel, É Gomez. "Complications of chemotherapy, a basic science update." La Presse Médicale, 2013: 42 (9), pp. e352-e361.
[64]
Morris, G., M. Berk, H. Klein, K. Walder, P. Galecki, and M., Maes. "Nitrosative stress, hypernitrosylation, and autoimmune responses to nitrosylated proteins: new pathways inneuroprogressive disorders including depression and chronic fatigue syndrome." Molecular neurobiology, 2016: 1-21.
[65]
Murray, S, A. O. A Odupitan, B. P Murray, and A. R. and Edwards, R. J Boobis. "Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline." xenobiotica, 2001: 31 (3), pp. 135-151.
[66]
O’brien, M. E. R., N. Wigler, M. C. B. C. S. G. Inbar, R., Rosso, E., Grischke, and A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P. and Orlandi, F. Santoro. "Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomalconventional doxorubicin for first-line treatment of metastatic breast cancer." Annals of oncology, 2004: 440-449.
[67]
Yang L, Luo C, Chen C, Wang X, Shi W, Liu J.. All-trans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathway. Br J Pharmacol. 2016; 173 (2): 357-71.
[68]
Olson, R. D., P. S. Mushlin, D. E. Brenner, S. Fleischer, B. J. Cusack, and B. K. and Boucek, R. J., 1988 Chang. "Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.." Proceedings of the National Academy of Sciences, 1988: 3585-3589.
[69]
Paridaens, R., et al. "Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.." Journal of clinical oncology, 2000: 724-724.
[70]
Poizat, C, P. L Puri, Y. and Kedes, L Bai, and. "Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells.." Molecular and cellular biology, 2005: 25 (7), pp 2673-2687.
[71]
Praga, C., et al. "Adriamycin cardiotoxicity: a survey of 1273 patients.." Cancer treatment reports, 1979: 63 (5), pp. 827.
[72]
Rao, M. R, M. C. Palada, and B. N Becker. " Medicinal and aromatic plants in agroforestry systems. In New Vistas in Agroforestry." Springer Netherlands, 2004: 107-122.
[73]
Rousselle, C., P. Clair, J. M. Lefauconnier, M. Kaczorek, and J. M. and Temsamani, J., Scherrmann. "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy." Molecular pharmacology, 2000: 679-686.
[74]
Saeed, N. M., El-Naga, R. N., El-Bakly, W. M., Abdel-Rahman, H. M., ElDin, R. A. S. and El-Demerdash, E.,. "Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: a mechanistic study." Biochemical pharmacology, 2015: 145-155.
[75]
Salvatorelli, E, and P. and Minotti, G Menna. "Managing anthracycline-induced cardiotoxicity: beginning with the end in mind." Future cardiology, 2015: 11 (4), pp. 363-366.
[76]
Sayed-Ahmed, M. M, M. M Khattab, M. Z. Gad, and A. M. M Osman. "Increased Plasma Endothelin-1 and Cardiac Nitric Oxide during Doxorubicin-Induced Cardiomyopathy.." Basic & Clinical Pharmacology & Toxicology, 2001: 89 (3), pp. 140-144.
[77]
Sentex, E, J. P Sergiel, and A. and Grynberg, A Lucien. "Is the cytoprotective effect of trimetazidine associated with lipid metabolism?" The American journal of cardiology, 1998: 82 (5), pp. 18K-24K.
[78]
Shamseddine, A. A, et al. "P53-dependent upregulation of neutral sphingomyelinase-2: role in doxorubicin-induced growth arrest.." Cell death & disease, 2015: 6 (10), p. e1947.
[79]
Šimůnek, T., M. Štěrba, O. Popelová, M. Adamcová, and R. and Geršl, V., Hrdina. "Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.." Pharmacological Reports, 2009: 154-171.
[80]
Sin, T. K., et al. "SIRT1-dependent myoprotective effects of resveratrol on muscle injury induced by compression. Frontiers in physiology." Frontiers in physiology, 2014: 293-293.
[81]
Suravajhala, R, R Poddar, S. Nallapeta, and S Ullah. "Xanthine Derivatives: A Molecular Modeling Perspective. In Agricultural Bioinformatics." Springer India., 2014: pp. 283-291.
[82]
Suzuki, T, et al. "Elevated B-type natriuretic peptide levels after anthracycline administration.." American heart journal, 1998: 136 (2), pp. 362-363.
[83]
Tacar, O., and P. and Dass, C. R. Sriamornsak. "Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems." Journal of Pharmacy and Pharmacology, 2013; 157-170.
[84]
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D. and Liu, L. F., "Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II." Science, 1984: 466-468.
[85]
Torre-Amione, G. Immune activation in chronic heart failure. The American journal of cardiology, 2005: 95 (11), pp. 3-8.
[86]
Tsuruo, T., H. Iida, and S. and Sakurai, Y Tsukagoshi. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer research, 1982: 42 (11), pp. 4730.
[87]
Tusi, S. K, L Khalaj, G Ashabi, M. Kiaei, and F Khodagholi. "Alginate oligosaccharide protects against endoplasmic reticulum-and mitochondrial-mediated apoptotic cell death and oxidative stress." Biomaterials, 2011.: 32 (23), pp. 5438-5458.
[88]
Van Asperen, J., van Tellingen, O. and Beijnen, J. H., "The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.." Drug Metabolism and Disposition, 2000: 264-267.
[89]
van der Veen, A. H, J. H de Wilt, A. M Eggermont, S. T van Tiel, and A. L. and ten Hagen, T. L Seynhaeve. "TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects." British journal of cancer, 2000: 82 (4) p. 973.
[90]
Von Hoff, D. D., M. W. Layard, P. Basa, H. L. Davis, A. L. Von Hoff, and M. and Muggia, F. M., Rozencweig. "Risk factors for doxorubicin-lnduced congestive heart failure.." Annals of internal medicine, 1979: 710-717.
[91]
Zhan Sun, Bin Yan, Wen Yan Yu, Xueping Yao, Xiaojuan Ma, Geli Sheng, and Qi Ma. Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. Exp Ther Med. 2016 Sep; 12 (3): 1879–1884.
[92]
Wang, H, et al. "Cardioprotective effects of 20 (S)-ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo.." Evidence-Based Complementary and Alternative Medicine, 2012.
[93]
Weiss, RB. "The anthracyclines: will we ever find a better doxorubicin?" InSeminars in oncology 19 (1992): 670-686.
[94]
Wouters, K. A, L Kremer, T. L Miller, and E. H. and Lipshultz, S. E Herman. "Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies." British journal of haematology, 2005: 131 (5), pp. 561-578.
[95]
Yanavitski, M., and M. M. Givertz. "Novel biomarkers in acute heart failure." Current heart failure reports, 2011: 8 (3), pp. 206-211.
[96]
Yang, F., S. S. Teves, and C. J. and Henikoff, S. Kemp. "Doxorubicin, DNA torsion, and chromatin dynamics. Biochimica et Biophysica Acta (BBA)-." Reviews on Cancer, 2014: 84-89.
[97]
Zhu, H, et al. Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin. Oncotarget, 2014: 6 (5), pp. 3254-3267.
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-688-8931